(Information sent by the signatory company)
PLANTATION, Fla., Dec. 12, 2022/PRNewswire/ — Goodwin Biotechnology, Inc. announces its new name, GBI, as part of a rebranding initiative to commemorate its 30th anniversary. This includes a new name, logo and website to reflect its evolution from an early stage clinical manufacturing Contract Development and Manufacturing Organization (CDMO) to a commercial CDMO ready in 2023!
GBI’s 30 years of offering a Single Source Solution™ of end-to-end biomanufacturing services has allowed us to grow and maintain a trusted customer base. The company has reached a critical milestone with the initiation of multiple biologics license application (BLA) enablement activities in 2023 to better serve long-standing customers. Comprehensive capabilities include analytical method transfer, documentation, upstream cell culture development, cGMP cell banking, downstream purification development, cGMP clinical and commercial drug substance manufacturing, bioconjugation, final drug product aseptic fill finish, and testing of stability.
Under the leadership of CEO, Darrin Schellin, the vision of GBI’s new brand will translate into the company’s DNA by leveraging the breadth of its business experience and the innovative capabilities of our new business expansion. This initiative will solidify our position that GBI supports its clients throughout the life of their projects and will continue to offer a unique “white glove” service that other larger conglomerate CDMOs cannot offer.
“We are an end-to-end CDMO, simplifying the process and speed to and through the clinic while maintaining end-to-end communication and the transparency, flexibility and agility our clients need,” shares CEO Darrin Schellin. “Take a holistic approach to activities based on our experience and advise our clients, who are often small and medium-sized companies, including ‘virtual biotechs’, who need CMC-related expertise, as we move through the process with them Consulting our infrastructure and agility enables us to launch early and late stage projects faster, and our expert teams rely on transparent and proactive project management to deliver to our clients and patients as quickly and efficiently as possible. years will mark a significant period of growth for us GBI is launching a new fully integrated cGMP biological facility that will expand our capabilities, with multiple bioreactor manufacturing trains ranging from 200 L to 2000 L and make it easier and faster than ever work with GBI, regardless of the scale or stage of your project! We thank our our customers for their continued and unwavering support. Our committed team is on a journey to commercialize our customers’ products as we move at GBI towards a late-stage clinical and commercial manufacturing approach. We have a cultural commitment to meet market expectations, and our highly experienced scientists and engineers are dedicated to solving our customers’ problems every day by guiding their products to the success they and their patients expect.”
About GBI
GBI is an exceptionally skilled and flexible US-based CDMO (Contract Development and Manufacturing Organization) offering a Single Source Solution™ to enhance the value of complex biopharmaceuticals for our customers. With 30 years of experience as an independent contract manufacturer, GBI has worked as a strategic partner with companies and institutions of all sizes, taking their products through clinical trials and rapidly to market. GBI provides cGMP manufacturing and process development services spanning drug substances and drug products to complex biologics, including multispecific antibodies, recombinant proteins, antibody-drug conjugates, and other classes of cell-based products. Building on its impressive track record, GBI has received numerous industry awards ranging from Frost’s Customer Value Award and Leadership
For more information, visit https://www.gbibio.com/
O
Contact: info@gbibio.com
GBI ISSUER officially known as Goodwin Biotechnology, Inc.
GBI 1850 N.W. 69th Avenue Plantation, FL 33313 Tel: 954-321-5300Fax: 954-587-6378info@gbibio.com
Logo – https://mma.prnewswire.com/media/1965652/gbi_logo_rgb_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/goodwin-biotechnology-inc-ahora-es-gbi-como-parte-de-su-iniciativa-de-cambio-de-marca-en-su-30-aniversario-301700532.html
